Skip to main content
    J

    Janux Therapeutics Inc (JANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.92
    -0.45 (-3.96%)

    Market Cap: $695.65M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Janux Therapeutics Inc (JANX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Janux Therapeutics reported revenue of $10.00M for the fiscal year ended Dec 31, 2025, down 5.6% from the year before. That year, net income was -$113.63M with a net margin of -1136.3%, operating cash flow was -$82.23M and free cash flow was -$83.28M. The quarter ended Sep 30, 2026 had revenue of $9.29M and net income of -$21.57M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$10.00M-5.6%100.0%-1576.7%-1136.3%
    Dec 2024$10.59M+31.0%100.0%-933.6%-651.6%
    Dec 2023$8.08M-6.1%100.0%-902.9%-721.2%
    Dec 2022$8.61M+136.8%100.0%-779.0%-732.2%
    Dec 2021$3.64MN/A100.0%-905.4%-898.3%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$10.00M$10.59M$8.08M$8.61M$3.64M$0$0
    Cost of revenue$0$0$0$0$0$0$6.00K
    Gross profit$10.00M$10.59M$8.08M$8.61M$3.64M$0-$6.00K
    Research and development$125.90M$68.39M$54.92M$53.44M$26.24M$3.04M$3.00M
    Operating income-$157.67M-$98.85M-$72.98M-$67.09M-$32.93M-$4.84M-$3.77M
    Net income-$113.63M-$68.99M-$58.29M-$63.06M-$32.67M-$6.78M-$4.24M
    EBITDAN/AN/AN/AN/AN/AN/A-$3.77M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$9.29M$10.27M$3.73M$7.88M$10.00M$0$0-$8.51M$439.00K$8.90M$1.25M$2.46M
    Gross profit$9.29M$10.27M$3.73M-$1.06M$10.00M$0$0-$20.81M$439.00K$8.90M$1.25M$2.46M
    Operating income-$31.26M-$31.69M-$34.21M-$42.40M-$35.25M-$45.12M-$34.90M-$29.02M-$35.84M-$13.82M-$20.16M-$16.14M
    Net income-$21.57M-$21.97M-$24.36M-$31.95M-$24.31M-$33.86M-$23.51M-$20.22M-$28.06M-$5.96M-$14.76M-$11.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.39M by $49.94M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$1.00B$1.06B$380.41M$364.01M$379.82M$16.22M$679.00K
    Current assets$975.89M$1.03B$349.24M$332.44M$377.02M$16.06M$658.00K
    Cash and equivalents$52.33M$430.61M$19.20M$51.43M$35.58M$7.81M$658.00K
    Total liabilities$44.74M$38.73M$36.06M$43.27M$13.50M$9.23M$8.62M
    Short-term debt$2.39M$1.75M$1.52M$763.00K$194.00K$751.00K$4.00M
    Shareholder equity$956.82M$1.02B$344.35M$320.74M$366.33M-$14.64M-$7.94M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$983.65M$1.01B$1.03B$1.01B$1.02B$1.03B$1.05B$1.06B$695.02M$691.41M$688.98M$380.41M
    Total liabilities$72.04M$79.67M$86.69M$50.70M$48.21M$41.70M$38.30M$38.73M$38.91M$33.73M$33.22M$36.06M
    Cash and equivalents$41.82M$27.77M$51.83M$52.33M$48.39M$52.45M$73.74M$430.61M$26.75M$14.66M$212.80M$19.20M
    Shareholder equity$911.61M$927.98M$941.53M$956.82M$976.55M$990.52M$1.01B$1.02B$656.10M$657.68M$655.76M$344.35M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$82.23M-$43.81M-$50.58M-$42.92M-$16.98M-$4.37M-$3.83M
    Capital expenditures$1.04M$359.00K$1.85M$6.45M$1.48M$0$1.48M
    Free cash flow-$83.28M-$44.17M-$52.42M-$49.37M-$18.46M-$4.37M-$5.31M
    Investing cash flow-$300.98M-$258.02M-$41.19M$58.27M-$340.96M$0-$340.96M
    Financing cash flow$4.95M$713.24M$59.55M$500.00K$386.52M$11.52M$4.00M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$25.18M$12.48M-$12.34M-$28.54M-$12.86M-$23.81M-$17.02M-$16.73M-$2.23M-$10.02M-$14.84M-$9.90M
    Capital expenditures$2.00K$202.00K$273.00K$106.00K$93.00K$473.00K$371.00K$42.00K$25.00K$95.00K$197.00K$515.00K
    Free cash flow-$25.18M$12.28M-$12.61M-$28.65M-$12.95M-$24.29M-$17.39M-$16.77M-$2.26M-$10.12M-$15.03M-$10.42M
    Last 12 quarters

    Frequently Asked Questions About JANX

    What is Janux Therapeutics' annual revenue?

    Janux Therapeutics reported revenue of $10.00M for the fiscal year ended Dec 31, 2025.

    How fast is Janux Therapeutics' revenue growing?

    Revenue was down 5.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.1%.

    Is Janux Therapeutics profitable?

    No. Janux Therapeutics reported net income of -$113.63M for the fiscal year ended Dec 31, 2025, with a net margin of -1136.3%.

    How much free cash flow does JANX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$82.23M minus capital expenditures of $1.04M produced free cash flow of -$83.28M.

    How much debt does Janux Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.39M and cash and equivalents of $52.33M.